These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 14759625)

  • 1. Evaluating multiple sclerosis.
    Tullman MJ; Lublin FD
    J Neurol Sci; 2004 Mar; 218(1-2):1-2. PubMed ID: 14759625
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond.
    D'Souza M; Kappos L; Czaplinski A
    J Neurol Sci; 2008 Nov; 274(1-2):76-9. PubMed ID: 18817932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome measures in multiple sclerosis.
    Amato MP; Portaccio E
    J Neurol Sci; 2007 Aug; 259(1-2):118-22. PubMed ID: 17376487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. You get what you measure: evaluating endpoints in MS clinical trials.
    Marrie RA
    Neurology; 2008 Aug; 71(9):620-1. PubMed ID: 18685132
    [No Abstract]   [Full Text] [Related]  

  • 6. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Hayes KC
    Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine and methotrexate in multiple sclerosis.
    Fernández O; Fernández V; De Ramón E
    J Neurol Sci; 2004 Aug; 223(1):29-34. PubMed ID: 15261557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to "Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients".
    Padua L; Nociti V; Bartalini S; Patti F; Quattrone A; Tonali P; Ulivelli M; Valentino P; Zappia M; Batocchi AP
    J Neurol Sci; 2007 Feb; 253(1-2):106. PubMed ID: 17215006
    [No Abstract]   [Full Text] [Related]  

  • 11. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodology of clinical trials in multiple sclerosis.
    Mitsikostas DD
    Neurol Sci; 2006 Sep; 27 Suppl 5():S362-4. PubMed ID: 16998721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
    Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 15. MRI as an outcome in multiple sclerosis clinical trials.
    Tenser RB
    Neurology; 2009 Dec; 73(22):1933-4; author reply 1934. PubMed ID: 19949044
    [No Abstract]   [Full Text] [Related]  

  • 16. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation and multiple sclerosis].
    Béthoux F
    Ann Readapt Med Phys; 2005 Jul; 48(6):369-75. PubMed ID: 15963830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy.
    Ozakbas S; Akdede BB; Kösehasanogullari G; Aksan O; Idiman E
    J Neurol Sci; 2007 May; 256(1-2):30-4. PubMed ID: 17379247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse, remission, and progression in multiple sclerosis.
    McDonald WI
    N Engl J Med; 2000 Nov; 343(20):1486-7. PubMed ID: 11078776
    [No Abstract]   [Full Text] [Related]  

  • 20. How much can we learn from long-term extension trials in multiple sclerosis?
    Noseworthy JH
    Neurology; 2006 Sep; 67(6):930-1. PubMed ID: 17000954
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.